Palisade Bio (PALI) Long-Term Debt Repayments (2012 - 2017)
Palisade Bio (PALI) reported Long-Term Debt Repayments of $2.5 million for Q2 2017, up 125.24% year-over-year from $1.1 million in Q2 2016, and up 108.02% on a QoQ basis from $1.2 million in Q1 2017.
Palisade Bio (PALI) has 5 years of Long-Term Debt Repayments data on file, last reported at $2.5 million in Q2 2017.
- Quarterly Long-Term Debt Repayments rose 125.24% year-over-year to $2.5 million in Q2 2017, while the trailing twelve-month figure through Dec 2017 was $3.8 million (down 17.59% YoY) and the FY2017 annual result came in at $3.8 million, down 17.59% from the prior year.
- Long-Term Debt Repayments climbed to $2.5 million in Q2 2017 per PALI's latest filing, from $1.2 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $2.5 million in Q2 2017 and bottomed at $12096.0 in Q4 2014.
- The 4-year median for Long-Term Debt Repayments is $1.1 million (2016), against an average of $1.0 million.
- The widest annual swing landed in 2015, when Long-Term Debt Repayments soared 9441.58%; it then increased 2.9% in 2016.
- Tracing PALI's Long-Term Debt Repayments over 4 years: stood at $12096.0 in 2014, then soared by 9441.58% to $1.2 million in 2015, then rose by 2.9% to $1.2 million in 2016, then surged by 114.13% to $2.5 million in 2017.
- Per Business Quant, the three latest PALI Long-Term Debt Repayments figures stand at $2.5 million (Q2 2017), $1.2 million (Q1 2017), and $1.2 million (Q4 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 2.54 Mn |
| Jun 30, 2017 | 2.54 Mn |
| Mar 31, 2017 | 1.22 Mn |
| Mar 31, 2017 | 1.22 Mn |
| Dec 31, 2016 | 1.19 Mn |
| Dec 31, 2016 | 1.19 Mn |
| Sep 30, 2016 | 1.16 Mn |
| Sep 30, 2016 | 1.16 Mn |
| Jun 30, 2016 | 1.13 Mn |
| Jun 30, 2016 | 1.13 Mn |
| Mar 31, 2016 | 1.10 Mn |
| Mar 31, 2016 | 1.10 Mn |
| Dec 31, 2015 | 1.15 Mn |
| Dec 31, 2015 | 1.15 Mn |
| Dec 31, 2014 | 12,096.00 |
| Dec 31, 2014 | 12,096.00 |
| Sep 30, 2014 | 492,230.00 |
| Sep 30, 2014 | 492,230.00 |
| Jun 30, 2014 | 720,305.00 |
| Jun 30, 2014 | 720,305.00 |
| Mar 31, 2014 | 704,818.00 |
| Mar 31, 2014 | 704,818.00 |
| Dec 31, 2012 | -16,272.00 |
| Dec 31, 2012 | -16,272.00 |
| Sep 30, 2012 | 16,272.00 |
| Sep 30, 2012 | 16,272.00 |